darunavir has been researched along with Adverse Drug Event in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Brites, C; Netto, EM; Patiño Escarcina, JE | 1 |
| Chen, L; He, G; Jia, Y; Tian, X; Wang, K; Yao, Y | 1 |
| Cetin, I; Dalzero, S; Degli Antoni, A; Floridia, M; Francisci, D; Frisina, V; Liuzzi, G; Maccabruni, A; Masuelli, G; Ravizza, M; Sansone, M; Simonazzi, G; Tamburrini, E; Tassis, B | 1 |
| Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X | 1 |
| Amara, A; Bisdomini, E; Boffito, M; Cerrone, M; Elliot, ER; Else, L; Khoo, S; Owen, A | 1 |
| Hamid, M; McGowan, M; Meaney, CJ; O'Connor, M; Su, W | 1 |
| Arathoon, E; Baraldi, E; Lavreys, L; Lim, PL; Opravil, M; Schneider, S; Van De Casteele, T | 1 |
| Crespo, M; Curran, A; Domingo, P; Fernández, I; Imaz, A; Iribarren, JA; Knobel, H; Martínez, E; Monteiro, P; Peñaranda, M; Podzamczer, D; Villar, J | 1 |
| Berrio-Galan, D; Bravo, I; Clotet, B; Llibre, JM; Miranda, C; Moltó, J; Paredes, R; Pérez-Alvarez, N; Pérez-Alvarez, S; Santos, JR | 1 |
| Hung, CC; Lin, KY | 1 |
| Assoumou, L; Benalycherif, A; Cabié, A; Costagliola, D; Duvivier, C; Girard, PM; Joly, V; Lambert-Niclot, S; Landman, R; Marcelin, AG; Peytavin, G; Pialoux, G; Samri, A; Slama, L; Valin, N | 1 |
| Antinori, A; Arribas, JR; Bicer, C; Girard, PM; Hadacek, B; Moecklinghoff, C; Netzle-Sveine, B; Ripamonti, D | 1 |
5 trial(s) available for darunavir and Adverse Drug Event
| Article | Year |
|---|---|
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Young Adult | 2019 |
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomiz
Topics: Adult; Africa; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
8 other study(ies) available for darunavir and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Raltegravir Potassium; Retrospective Studies; Salvage Therapy; Treatment Outcome; Viral Load | 2023 |
Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Darunavir; Data Mining; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pharmacovigilance; Pregnancy; Pregnancy Complications; United States; United States Food and Drug Administration; Young Adult | 2021 |
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Cholesterol; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Triglycerides; Viral Load | 2018 |
Treatment of prolonged tacrolimus toxicity using phenytoin in a haemodialysis patient.
Topics: Darunavir; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Male; Middle Aged; Phenytoin; Renal Dialysis; Ritonavir; Tacrolimus | 2019 |
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2014 |
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Clinical relevance of cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Bacterial Infections; Darunavir; Drug Hypersensitivity; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination | 2015 |